Mesenchymal Stem Cell (MSC) Therapy for Parkinson's Disease represents a distinct therapeutic approach from the dopaminergic neuron replacement strategies (iPSC/ESC-derived neurons). While cell replacement aims to substitute lost dopaminergic neurons, MSC therapy focuses on neuroprotection, immunomodulation, and trophic support to preserve remaining neurons and slow disease progression.
| Property |
Value |
| Treatment Name |
Mesenchymal Stem Cell (MSC) Therapy for PD |
| Cell Type |
Mesenchymal Stromal Cells |
| Target Indication |
Parkinson's Disease |
| Mechanism |
Neurotrophic secretion, immunomodulation, mitochondrial transfer |
| Delivery Routes |
Intravenous, intrathecal, stereotactic |
| Clinical Stage |
Phase 1/2 trials |
Several factors make MSC-based neuroprotection an attractive complementary approach:
- Preserve Existing Circuitry: Rather than rebuilding neural circuits (which requires precise integration), MSC therapy protects the substantia nigra pars compacta neurons that remain
- Multi-Target Mechanism: Addresses multiple pathogenic pathways simultaneously (inflammation, oxidative stress, mitochondrial dysfunction)
- Accessibility: MSCs can be delivered via less invasive routes than stereotactic neuron transplantation
- Repeat Dosing: Multiple administrations possible as disease progresses
- Combination Potential: Can be combined with other disease-modifying approaches
Parkinson's disease involves:
MSC therapy directly addresses several of these mechanisms.
MSCs exert powerful immunomodulatory effects critical for PD:
Microglial Modulation
- Shift microglia from pro-inflammatory M1 to protective M2 phenotype
- Reduce production of pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ)
- Increase anti-inflammatory cytokines (IL-10, TGF-β)
T-Cell Regulation
- Suppress pro-inflammatory T-cell responses
- Promote regulatory T-cell (Treg) populations
- Reduce autoimmunity that may contribute to neurodegeneration
MSCs secrete multiple neurotrophic factors that support dopaminergic neuron survival:
| Factor |
Function in PD |
| GDNF |
Potent neurotrophin for dopaminergic neurons; promotes survival and process outgrowth |
| BDNF |
Supports neuronal plasticity, synaptic function, and dopamine signaling |
| VEGF |
Promotes neurovascular unit health, improves blood-brain barrier function |
| IGF-1 |
Supports neuronal metabolism and survival |
| HGF |
Anti-inflammatory and neuroprotective properties |
A unique mechanism by which MSCs transfer functional mitochondria to damaged neurons:
- Tunneling Nanotubes: Form direct cytoplasmic connections with stressed neurons
- Metabolic Rescue: Restore ATP levels in neurons with impaired energy metabolism
- Bioenergetic Support: Improve neuronal viability under oxidative stress conditions
- ** Particularly Relevant in PD**: Mitochondrial dysfunction is a core feature of Parkinson's disease pathogenesis
- Secreted factors activate pro-survival signaling cascades (PI3K/Akt, MAPK/ERK)
- Reduce caspase activation and programmed cell death
- Protect neurons from excitotoxicity
- Preserve synaptic connections
Emerging evidence suggests MSCs may influence alpha-synuclein pathology:
| Source |
Advantages |
Disadvantages |
| Bone Marrow (Autologous) |
Well-characterized, no immune issues |
Older cells, variable potency |
| Bone Marrow (Allogeneic) |
Younger cells, standardized |
Immune rejection risk |
| Umbilical Cord (Wharton's Jelly) |
Higher proliferative capacity, immunomodulatory |
Allogeneic, ethical considerations |
| Adipose Tissue |
Abundant source, easy collection |
Variable differentiation potential |
| Dental Pulp |
Neural crest origin, easy access |
Limited expansion capacity |
¶ Completed and Active Trials
| Trial |
Sponsor |
Phase |
Cell Source |
Route |
Status |
| NCT00911326 |
Multiple |
I/II |
Autologous BM-MSC |
Intrastriatal |
Completed |
| NCT01827180 |
University of Poona |
I/II |
Autologous BM-MSC |
Intravenous |
Completed |
| NCT02611167 |
Saudi German Hospital |
I |
Umbilical Cord MSC |
Intrathecal |
Completed |
| NCT04521368 |
Shanghai Sixth People's Hospital |
I/II |
Umbilical Cord MSC |
Intravenous |
Recruiting |
| NCT04881461 |
HEALIOS K.K. (Japan) |
I/II |
Allogeneic MSC |
Intravenous |
Active |
Phase 1/2 Trials (2014-2016)
- MSC transplantation was safe and well-tolerated
- Some patients showed improved motor scores (UPDRS Part III)
- No significant adverse events related to cell administration
- Reference: PMID 24721108, PMID 28182767
Mechanism Evidence
- Elevated neurotrophic factors in CSF of treated patients
- PET imaging showed reduced neurodegeneration in some patients
- Immunomodulatory effects confirmed in biomarker studies
HEALIOS K.K. (Japan)
- Allogeneic MSC product
- Phase 1/2 trial for PD
- Focus on safety and preliminary efficacy
International Consortium Trials
- Multi-center trials combining different MSC sources
- Focus on optimizing delivery routes and cell dosing
| Route |
Advantages |
Challenges |
Clinical Use |
| Intravenous |
Minimally invasive, systemic effect |
Limited CNS penetration, first-pass metabolism |
Most common |
| Intrathecal |
Direct CSF delivery, reaches brain surfaces |
Invasive, requires lumbar puncture |
Growing use |
| Stereotactic |
Precise brain targeting, high local concentration |
Most invasive, surgical risk |
Some trials |
| Intra-arterial |
High CNS exposure |
Emboli risk |
Research |
For PD, intrathecal or intravenous delivery is most commonly used:
- Allows repeated administrations
- Targets neuroinflammation systemically
- Less invasive than neurosurgery
Stereotactic delivery targets substantia nigra directly but is more invasive.
| Factor |
MSC Therapy |
iPSC/ESC Neuron Therapy |
| Primary Mechanism |
Neuroprotection, trophic support |
Cell replacement, dopamine production |
| Stage |
Phase 1/2 |
Phase 1/2/3 (PD), Phase 1 (PD) |
| Delivery |
IV/Intrathecal |
Stereotactic surgery |
| Invasiveness |
Lower |
Higher |
| Repeat Dosing |
Yes |
Limited |
| Dopamine Restoration |
Indirect via trophic support |
Direct |
| Risk of Tumor |
Very low |
Moderate (pluripotent cells) |
| Manufacturing |
Relatively simple |
Complex |
| Timeline to Access |
Earlier |
Later |
These approaches are not mutually exclusive:
- Early Disease: MSC therapy to protect neurons and slow progression
- Later Disease: Neuron replacement when significant cell loss has occurred
- Combination: MSC therapy alongside neuron replacement for synergistic effects
¶ Companies and Programs
| Company |
Product |
Mechanism |
Status |
| BrainStorm Cell Therapeutics |
MSC-NTF (NurOwn platform) |
Neurotrophic factor-secreting MSCs |
ALS completed; PD preclinical |
| HEALIOS K.K. |
Allogeneic MSCs |
Immunomodulation, trophic support |
Phase 1/2 (Japan) |
| Cynata Therapeutics |
CYP-001 |
iPSC-derived MSCs |
Phase 2 (GvHD); PD program emerging |
- Multiple universities in Korea, Japan, China, and Europe have active MSC-PD programs
- International Stem Cell Corporation (ISCO) exploring MSC derivatives for PD
¶ Therapeutic Potential and Challenges
- Disease Modification: Targets multiple pathogenic pathways simultaneously
- Neuroprotection: Preserves remaining dopaminergic neurons
- Symptomatic Relief: May improve motor function through trophic support
- Autologous Option: Patient's own cells reduce rejection risk
- Repeat Administrations: Can be re-treated as disease progresses
- Accessible: Less invasive than surgical cell transplantation
- Limited CNS Delivery: Blood-brain barrier limits intravenous delivery
- Variable Potency: MSC preparations vary between donors and sources
- Survival in CNS: Unclear how long administered MSCs persist
- Optimal Dose: Not established for PD
- Durability: Unknown duration of benefit
- Regulatory Pathway: Cell therapy regulatory challenges
MSC therapy may be most appropriate for:
- Early-to-mid stage PD (Hoehn & Yahr 1-3)
- Patients with significant neuroinflammation markers
- Those seeking disease-modifying approaches
- Patients with contraindications to surgical interventions
MSC therapy may be enhanced when combined with:
- GDNF/BDNF Direct Delivery: Combined trophic support
- Small Molecules: MAO-B inhibitors, dopamine agonists
- Immunomodulatory Drugs: Anti-inflammatory agents
- Physical Therapy: Rehabilitation to enhance functional outcomes
- Gene Therapy: AAV-based neurotrophic factor expression
- MSC plus neurotrophic factor combination trials in planning
- Gene-modified MSCs (enhanced GDNF secretion) in preclinical development
- MSC-derived exosomes as cell-free alternative
- Generally well-tolerated across trials
- Common adverse events: Headache, injection site pain
- No significant immune reactions with autologous cells
- No tumor formation observed in long-term follow-up
- Low rates of serious adverse events
- Continued monitoring for potential delayed effects
- Assessment of durability of benefit
- Impact on disease progression over years
- Gene-Enhanced MSCs: Engineering MSCs to produce higher GDNF/BDNF levels
- Exosome Therapy: Cell-free alternative using MSC-derived exosomes
- Biomaterial Scaffolds: Supporting MSC survival and distribution
- Combination Approaches: MSC therapy with other disease-modifying agents
- Larger, controlled trials with standardized endpoints
- Biomarker development to predict response
- Optimal patient selection criteria
- Long-term follow-up studies
- Comparison of delivery routes